Approvable designations; Priority review; Fast-track designations; Orphan drug designations; Nonapprovable designations
Approvable designations
Priority review
Fast-track designations
Nonapprovable designations
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More